Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 gel for prevention of taxane-induced peripheral neuropathy and local cutaneous side effects
ISRCTN43521285Phase 2Completed
- Sponsor
- Tarian Pharma
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brimonidine in chemotherapy-induced peripheral neuropathy (CIPN) and cutaneous reaction (3 arms), sponsored by Tarian Pharma. Primary endpoint: Peripheral neuropathy symptoms. Started Sep 2025; status: completed.
02
Drugs
brimonidine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)cutaneous reaction
Beyond the preview
Go deeper on ISRCTN43521285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43521285.